AAPL287.68+5.94 (+2.11%) ▲|ABBV251.31-3.00 (-1.18%) ▼|ABT90.94-1.77 (-1.91%) ▼|ACN124.80+0.06 (+0.05%) ▲|ADBE204.94-1.50 (-0.72%) ▼|AMAT737.76+43.12 (+6.21%) ▲|AMD582.51+43.02 (+7.97%) ▲|AMGN362.38+1.83 (+0.51%) ▲|AMT164.73-3.94 (-2.34%) ▼|AMZN237.74-2.40 (-1.00%) ▼|AVGO378.85+6.40 (+1.72%) ▲|AXP339.50-1.39 (-0.41%) ▼|BA215.84+1.15 (+0.54%) ▲|BAC57.06-0.83 (-1.43%) ▼|BKNG178.20-4.21 (-2.31%) ▼|BLK960.00+9.83 (+1.03%) ▲|BMY57.87-0.69 (-1.18%) ▼|BNY144.79+0.99 (+0.69%) ▲|BRK-B499.25+3.25 (+0.66%) ▲|C139.80-2.69 (-1.89%) ▼|CAT1,065.48+32.29 (+3.13%) ▲|CL91.57-0.83 (-0.90%) ▼|CMCSA24.46+0.24 (+0.97%) ▲|COF201.29-0.99 (-0.49%) ▼|COP103.99-0.21 (-0.20%) ▼|COST934.68-12.00 (-1.27%) ▼|CRM157.26-0.67 (-0.42%) ▼|CSCO117.52-0.18 (-0.15%) ▼|CVS103.91+0.33 (+0.32%) ▲|CVX166.05-2.43 (-1.44%) ▼|DE633.53+8.52 (+1.36%) ▲|DHR191.06-1.72 (-0.89%) ▼|DIS96.48-1.40 (-1.43%) ▼|DUK127.37-0.97 (-0.75%) ▼|EMR143.27+0.45 (+0.32%) ▲|FDX312.12-13.28 (-4.08%) ▼|GD354.24+6.17 (+1.77%) ▲|GE372.51-1.21 (-0.32%) ▼|GEV1,172.02+69.51 (+6.30%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.10-0.24 (-0.31%) ▼|GOOG353.94+2.66 (+0.76%) ▲|GOOGL357.21+3.56 (+1.01%) ▲|GS1,012.89-7.32 (-0.72%) ▼|HD353.01+2.20 (+0.63%) ▲|HON221.55-6.25 (-2.74%) ▼|IBM282.10+4.10 (+1.47%) ▲|INTC140.61+8.89 (+6.75%) ▲|INTU261.52-4.88 (-1.83%) ▼|ISRG399.51-6.46 (-1.59%) ▼|JNJ254.93-3.59 (-1.39%) ▼|JPM327.10-2.29 (-0.70%) ▼|KO81.13-1.52 (-1.84%) ▼|LIN518.90+7.84 (+1.53%) ▲|LLY1,206.97-22.96 (-1.87%) ▼|LMT509.05+6.98 (+1.39%) ▲|LOW220.66+1.01 (+0.46%) ▲|LRCX436.60+25.69 (+6.25%) ▲|MA513.44+3.80 (+0.75%) ▲|MCD270.33+3.15 (+1.18%) ▲|MDLZ57.83-2.32 (-3.86%) ▼|MDT78.50-2.44 (-3.01%) ▼|META560.70-1.91 (-0.34%) ▼|MMM162.02-0.42 (-0.26%) ▼|MO72.03-2.02 (-2.73%) ▼|MRK128.44-0.95 (-0.73%) ▼|MS209.35-2.37 (-1.12%) ▼|MSFT371.19+2.62 (+0.71%) ▲|MU1,162.07+16.79 (+1.47%) ▲|NEE88.09-0.57 (-0.64%) ▼|NFLX71.87-1.91 (-2.59%) ▼|NKE41.17-0.31 (-0.76%) ▼|NOW99.31-0.66 (-0.66%) ▼|NVDA198.69+3.72 (+1.91%) ▲|ORCL147.31-0.45 (-0.30%) ▼|PEP135.20-3.49 (-2.51%) ▼|PFE24.10-0.28 (-1.13%) ▼|PG146.35-2.10 (-1.41%) ▼|PLTR116.58+0.88 (+0.76%) ▲|PM180.71-2.16 (-1.18%) ▼|QCOM184.23-4.49 (-2.38%) ▼|RTX189.60+2.27 (+1.21%) ▲|SBUX102.17-1.90 (-1.82%) ▼|SCHW92.12+1.57 (+1.73%) ▲|SO96.20-0.55 (-0.57%) ▼|SPG224.14-3.43 (-1.51%) ▼|T20.65-1.18 (-5.39%) ▼|TMO503.65-2.77 (-0.55%) ▼|TMUS167.70-6.28 (-3.61%) ▼|TSLA421.79+9.95 (+2.42%) ▲|TXN299.68+14.20 (+4.97%) ▲|UBER72.17-3.34 (-4.42%) ▼|UNH416.17-3.66 (-0.87%) ▼|UNP271.92-0.78 (-0.29%) ▼|UPS107.49-0.52 (-0.48%) ▼|USB60.57-0.20 (-0.32%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.32-1.79 (-4.05%) ▼|WFC82.79-0.72 (-0.86%) ▼|WMT113.08-1.52 (-1.33%) ▼|XOM136.52+0.46 (+0.33%) ▲|AAPL287.68+5.94 (+2.11%) ▲|ABBV251.31-3.00 (-1.18%) ▼|ABT90.94-1.77 (-1.91%) ▼|ACN124.80+0.06 (+0.05%) ▲|ADBE204.94-1.50 (-0.72%) ▼|AMAT737.76+43.12 (+6.21%) ▲|AMD582.51+43.02 (+7.97%) ▲|AMGN362.38+1.83 (+0.51%) ▲|AMT164.73-3.94 (-2.34%) ▼|AMZN237.74-2.40 (-1.00%) ▼|AVGO378.85+6.40 (+1.72%) ▲|AXP339.50-1.39 (-0.41%) ▼|BA215.84+1.15 (+0.54%) ▲|BAC57.06-0.83 (-1.43%) ▼|BKNG178.20-4.21 (-2.31%) ▼|BLK960.00+9.83 (+1.03%) ▲|BMY57.87-0.69 (-1.18%) ▼|BNY144.79+0.99 (+0.69%) ▲|BRK-B499.25+3.25 (+0.66%) ▲|C139.80-2.69 (-1.89%) ▼|CAT1,065.48+32.29 (+3.13%) ▲|CL91.57-0.83 (-0.90%) ▼|CMCSA24.46+0.24 (+0.97%) ▲|COF201.29-0.99 (-0.49%) ▼|COP103.99-0.21 (-0.20%) ▼|COST934.68-12.00 (-1.27%) ▼|CRM157.26-0.67 (-0.42%) ▼|CSCO117.52-0.18 (-0.15%) ▼|CVS103.91+0.33 (+0.32%) ▲|CVX166.05-2.43 (-1.44%) ▼|DE633.53+8.52 (+1.36%) ▲|DHR191.06-1.72 (-0.89%) ▼|DIS96.48-1.40 (-1.43%) ▼|DUK127.37-0.97 (-0.75%) ▼|EMR143.27+0.45 (+0.32%) ▲|FDX312.12-13.28 (-4.08%) ▼|GD354.24+6.17 (+1.77%) ▲|GE372.51-1.21 (-0.32%) ▼|GEV1,172.02+69.51 (+6.30%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.10-0.24 (-0.31%) ▼|GOOG353.94+2.66 (+0.76%) ▲|GOOGL357.21+3.56 (+1.01%) ▲|GS1,012.89-7.32 (-0.72%) ▼|HD353.01+2.20 (+0.63%) ▲|HON221.55-6.25 (-2.74%) ▼|IBM282.10+4.10 (+1.47%) ▲|INTC140.61+8.89 (+6.75%) ▲|INTU261.52-4.88 (-1.83%) ▼|ISRG399.51-6.46 (-1.59%) ▼|JNJ254.93-3.59 (-1.39%) ▼|JPM327.10-2.29 (-0.70%) ▼|KO81.13-1.52 (-1.84%) ▼|LIN518.90+7.84 (+1.53%) ▲|LLY1,206.97-22.96 (-1.87%) ▼|LMT509.05+6.98 (+1.39%) ▲|LOW220.66+1.01 (+0.46%) ▲|LRCX436.60+25.69 (+6.25%) ▲|MA513.44+3.80 (+0.75%) ▲|MCD270.33+3.15 (+1.18%) ▲|MDLZ57.83-2.32 (-3.86%) ▼|MDT78.50-2.44 (-3.01%) ▼|META560.70-1.91 (-0.34%) ▼|MMM162.02-0.42 (-0.26%) ▼|MO72.03-2.02 (-2.73%) ▼|MRK128.44-0.95 (-0.73%) ▼|MS209.35-2.37 (-1.12%) ▼|MSFT371.19+2.62 (+0.71%) ▲|MU1,162.07+16.79 (+1.47%) ▲|NEE88.09-0.57 (-0.64%) ▼|NFLX71.87-1.91 (-2.59%) ▼|NKE41.17-0.31 (-0.76%) ▼|NOW99.31-0.66 (-0.66%) ▼|NVDA198.69+3.72 (+1.91%) ▲|ORCL147.31-0.45 (-0.30%) ▼|PEP135.20-3.49 (-2.51%) ▼|PFE24.10-0.28 (-1.13%) ▼|PG146.35-2.10 (-1.41%) ▼|PLTR116.58+0.88 (+0.76%) ▲|PM180.71-2.16 (-1.18%) ▼|QCOM184.23-4.49 (-2.38%) ▼|RTX189.60+2.27 (+1.21%) ▲|SBUX102.17-1.90 (-1.82%) ▼|SCHW92.12+1.57 (+1.73%) ▲|SO96.20-0.55 (-0.57%) ▼|SPG224.14-3.43 (-1.51%) ▼|T20.65-1.18 (-5.39%) ▼|TMO503.65-2.77 (-0.55%) ▼|TMUS167.70-6.28 (-3.61%) ▼|TSLA421.79+9.95 (+2.42%) ▲|TXN299.68+14.20 (+4.97%) ▲|UBER72.17-3.34 (-4.42%) ▼|UNH416.17-3.66 (-0.87%) ▼|UNP271.92-0.78 (-0.29%) ▼|UPS107.49-0.52 (-0.48%) ▼|USB60.57-0.20 (-0.32%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.32-1.79 (-4.05%) ▼|WFC82.79-0.72 (-0.86%) ▼|WMT113.08-1.52 (-1.33%) ▼|XOM136.52+0.46 (+0.33%) ▲|
31.4 C
New York
Tuesday, June 30, 2026

Tag: research

newssourceFORcompanyinformationcontent1releasesmarket

NativePath Liposomal Vitamin C: Urgent 2025 Consumer Warning on Why Most Vitamin C Pills May Fail — And the 3-in-1 Formula Positioned for Better...

Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities. 
Public interest in vitamin C has surged in 2025 as consumers search for cleaner, more effective options beyond standard pills. Across TikTok, Reddit, and wellness forums, questions are rising about ingredient sources, absorption rates, and the difference between synthetic ascorbic acid and real, whole-food vitamin C. NativePath Liposomal Vitamin C is positioned within this growing trend, featuring an amla-based 3-in-1 formula designed for nutrient integrity and advanced delivery. It reflects a broader shift toward transparency, clean sourcing, and solutions that align with evolving health and wellness priorities.

Vertigenics – The Natural Vertigo Breakthrough Driving 2025 Interest in Balance and Brain Support Formulas

Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025 
Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025

Providence St. Joseph Hospital Foundation Establishes First-Ever Endowed Chairs to Advance Excellence in Cardiac and Cancer Care

Donor generosity provides lasting support for physician leadership, innovation and patient care in Orange County ORANGE, Calif., Aug. 13, 2025 /PRNewswire/ -- Today Providence St....

LungExpand Pro Gains 2025 Spotlight as Plant-Based Daily Support Formula Amid Rising Public Interest in Breathing Comfort and Respiratory Wellness

Growing interest in natural respiratory support draws attention to ingredient-first formulations like LungExpand Pro, blending plant extracts and nutrients often discussed for breathing comfort and daily lung health. 
Growing interest in natural respiratory support draws attention to ingredient-first formulations like LungExpand Pro, blending plant extracts and nutrients often discussed for breathing comfort and daily lung health.

Neuro Sharp Gains Recognition in 2025 as Your Ultimate Brain Enhancement Formula

Scientifically Formulated Nootropic Backed by 2025 Research for Sharper Focus and Cognitive Support 
Scientifically Formulated Nootropic Backed by 2025 Research for Sharper Focus and Cognitive Support

AlphaCur Gains Momentum in 2025 as a Leading Formula for Neuropathy Nerve Health Support

AlphaCur Introduces Ingredient-First Nerve Health Formula as Interest in Neuropathy Support and Long-Term Wellness Grows in 2025 
AlphaCur Introduces Ingredient-First Nerve Health Formula as Interest in Neuropathy Support and Long-Term Wellness Grows in 2025

Optiva Inc. Reports Second Quarter 2025 Financial Results

All amounts are stated in United States dollars unless otherwise indicated

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update.

Applied Therapeutics Reports Second Quarter 2025 Financial Results

- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD

Stardust Power Announces Q2 2025 Financial Results

Stardust Power Q2 2025 earnings release

Solventum Announces Launch of Secondary Offering of Common Stock

ST. PAUL, Minn., Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV, "Company" or "Solventum") today announced the launch of a secondary offering (the "Offering")...

FIEE Announces Fiscal 2025 First Half Unaudited Financial Results

First Half Revenue of $45,118Prepaid subscription fees received from customers for our SaaS service were $1.5 Million. HONG KONG, Aug. 13, 2025 /PRNewswire/ -- FiEE,...

Expion360 Reports Second Quarter 2025 Financial and Operational Results

Expion360 Reports Second Quarter 2025 Financial and Operational Results

Centria Autism Partners with University of Nevada, Reno to Launch Sponsored Master’s Cohort for Aspiring BCBAs

New initiative combines UNR's renowned ABA curriculum with full tuition sponsorship and Centria's structured practicum program FARMINGTON HILLS, Mich., Aug. 13, 2025 /PRNewswire/ -- Centria...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResearch

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers